Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PAK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAK2 Recombinant Protein (Kinase Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/E. coli expressed. |
View PAK2 Products |
| Gene Delivery | PAK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View PAK2 Products |
| Benchmark Ab | Anti-PAK2 Recombinant Antibody High-specificity positive control for Western Blot, ELISA, and IP. |
View PAK2 Products |
| Validator | PAK2 siRNA Set Validated knockdown pool for target specificity verification. |
View PAK2 Products |
| Related Target A | PAK1 Highly homologous Group I PAK family member. Crucial for off-target selectivity screening. |
View PAK1 Products |
| Related Target B | RAC1 Upstream GTPase activator of PAK2. Essential for pathway-level functional evaluation. |
View RAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Domain Homology (Selectivity vs PAK1/3) | Homolog panel proteins (PAK1, PAK2, PAK3) strictly verified by mass spectrometry and sequence analysis to ensure exact isoform matching. |
| Active Kinase Assay Interference | High-purity, endotoxin-controlled recombinant proteins minimize background noise in ADP-Glo and HTRF screening assays. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated positive controls included in the development pipeline. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for orthogonal target knockdown verification in cell-based assays. |
Live PAK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PAK2 therapeutics is intensifying, with major players shifting focus from traditional non-selective kinase inhibitors to isoform-selective small molecules and PROTACs (Proteolysis Targeting Chimeras). As first-generation pan-PAK inhibitors faced toxicity hurdles due to systemic PAK1/2 inhibition, the next wave of R&D is targeting highly selective PAK2 degradation or allosteric modulation to spare healthy tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Institutions, Biotech Startups | Solid Tumors (Breast, Colon, Glioblastoma) | Selectivity Assay (Need high-purity PAK1 vs PAK2 mutant & WT proteins) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Pioneers | Hematological Malignancies, Drug-Resistant Cancers | Ubiquitination & Ternary Complex Validation (Need sequence-verified full-length PAK2) |
| Gene Therapy / siRNA | RNAi Therapeutics Developers | Advanced Solid Tumors | Knockdown Validation (Need high-specificity siRNA and Lentivirus for cell lines) |